ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,01%
Bitcoin
67.714,89
0,34%
Brent Oil
81,295
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Molecular Partners AG (MOLN)

  7. Molecular Partners AG (MOLN) Notícias

MOLN

Molecular Partners (MOLN)

Molecular Partners AG
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MOLN
DataHoraFonteTítuloCódigoCompanhia
01/06/202409:00GlobeNewswire Inc.Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024NASDAQ:MOLNMolecular Partners AG
17/05/202407:25Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:MOLNMolecular Partners AG
16/05/202417:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MOLNMolecular Partners AG
16/05/202417:00GlobeNewswire Inc.Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 ProgramNASDAQ:MOLNMolecular Partners AG
29/04/202412:00GlobeNewswire Inc.Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action NASDAQ:MOLNMolecular Partners AG
19/04/202412:12GlobeNewswire Inc.Life Science Cares Launches in SwitzerlandNASDAQ:MOLNMolecular Partners AG
17/04/202412:12GlobeNewswire Inc.Molecular Partners Announces All Board Proposals Approved at the Annual General MeetingNASDAQ:MOLNMolecular Partners AG
26/03/202410:26GlobeNewswire Inc.Molecular Partners Publishes Invitation to Annual General Meeting 2024NASDAQ:MOLNMolecular Partners AG
14/03/202417:00GlobeNewswire Inc.Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023NASDAQ:MOLNMolecular Partners AG
01/03/202418:00GlobeNewswire Inc.Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor PresentationsNASDAQ:MOLNMolecular Partners AG
07/01/202418:00GlobeNewswire Inc.Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MOLNMolecular Partners AG
05/01/202418:00GlobeNewswire Inc.Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin TherapiesNASDAQ:MOLNMolecular Partners AG
14/12/202303:00GlobeNewswire Inc.Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor ConferencesNASDAQ:MOLNMolecular Partners AG
10/12/202314:00GlobeNewswire Inc.Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingNASDAQ:MOLNMolecular Partners AG
14/11/202303:00GlobeNewswire Inc.Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)NASDAQ:MOLNMolecular Partners AG
03/11/202313:00GlobeNewswire Inc.Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingNASDAQ:MOLNMolecular Partners AG
02/11/202303:00GlobeNewswire Inc.Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and ExpositionNASDAQ:MOLNMolecular Partners AG
01/11/202303:00GlobeNewswire Inc.Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation SummitNASDAQ:MOLNMolecular Partners AG
26/10/202317:00GlobeNewswire Inc.Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin PortfolioNASDAQ:MOLNMolecular Partners AG
13/09/202302:00GlobeNewswire Inc.Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual MeetingNASDAQ:MOLNMolecular Partners AG
24/08/202317:00GlobeNewswire Inc.Molecular Partners Reports H1 2023 Corporate Highlights and FinancialsNASDAQ:MOLNMolecular Partners AG
28/06/202309:35Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MOLNMolecular Partners AG
28/06/202309:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MOLNMolecular Partners AG
27/06/202302:00GlobeNewswire Inc.Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023NASDAQ:MOLNMolecular Partners AG
19/06/202313:00GlobeNewswire Inc.Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitNASDAQ:MOLNMolecular Partners AG
25/05/202318:01GlobeNewswire Inc.Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual MeetingNASDAQ:MOLNMolecular Partners AG
16/05/202317:00GlobeNewswire Inc.Molecular Partners to Participate in RBC Capital 2023 Global Healthcare ConferenceNASDAQ:MOLNMolecular Partners AG
12/05/202307:07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MOLNMolecular Partners AG
11/05/202317:00GlobeNewswire Inc.Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio StrategyNASDAQ:MOLNMolecular Partners AG
14/04/202302:00GlobeNewswire Inc.Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACRNASDAQ:MOLNMolecular Partners AG
 Apresentando as notícias mais relevantes sobre:NASDAQ:MOLN

Seu Histórico Recente

EU
FRSG00014GI1
SG Issuer Sg Issuer Mc D...
LSE
BK24
Citi Fun 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados